Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients

Judy Y. Ou, Holly Spraker-Perlman, Andrew C. Dietz, Rochelle R. Smits-Seemann, Sapna Kaul, Anne C. Kirchhoff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Survival estimates for soft tissue sarcomas (STS) and malignant bone tumors (BT) diagnosed in pediatric, adolescent, and young adult patients are not easily available. We present survival estimates based on a patient having survived a defined period of time (conditional survival). Conditional survival estimates for the short-term were calculated for patients from diagnosis to the first five years after diagnosis and for patients surviving in the long-term (up to 20 years after diagnosis). Methods We identified 703 patients who were diagnosed with a STS or BT at age ≤25 years from January 1, 1986 to December 31, 2012 at a large pediatric oncology center in Salt Lake City, Utah, United States. We obtained cancer type, age at diagnosis, primary site, and demographic data from medical records, and vital status through the National Death Index. Cancer stage was available for a subset of the cohort through the Utah Cancer Registry. Cox proportional hazards models, adjusted for age and sex, calculated survival estimates for all analyses. Results Short-term survival improves over time for both sarcomas. Short-term survival for STS from diagnosis (Year 0) did not differ by sex, but short-term survival starting from 1-year post diagnosis was significantly worse for male patients (Survival probability 1-year post-diagnosis [SP1]:77% [95% CI:71-83]) than female patients (SP1:86% [81–92]). Survival for patients who were diagnosed at age ≤10 years (Survival probability at diagnosis [SP0]:85% [79–91]) compared to diagnosis at ages 16–25 years (SP0:67% [59–75]) was significantly better at all time-points from diagnosis to 5-years post-diagnosis. Survival for axial sites (SP0:69% [63–75]) compared to extremities (SP0:84% [79–90]) was significantly worse from diagnosis to 1-year post-diagnosis. Survival for axial BT (SP0: 64% [54–74] was significantly worse than BT in the extremities (SP0:73% [68–79]) from diagnosis to 3-years post diagnosis. Relapsed patients of both sarcoma types had significantly worse short-term survival than non-relapsed patients. Long-term survival for STS in this cohort is 65% at diagnosis, and improves to 86% 5-years post-diagnosis. BT survival improves from 51% at diagnosis to 78% at 5-years post-diagnosis. Conclusion Conditional survival for short- and long-term STS and BT improve as time from diagnosis increases. Short-term survival was significantly affected by patients' sex, age at diagnosis, cancer site, and relapse status.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalCancer Epidemiology
Volume50
DOIs
StatePublished - Oct 1 2017

Fingerprint

Sarcoma
Young Adult
Pediatrics
Bone and Bones
Survival
Neoplasms
Extremities

Keywords

  • Cancer
  • Cancer survival
  • Epidemiology
  • Pediatrics

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Cite this

Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients. / Ou, Judy Y.; Spraker-Perlman, Holly; Dietz, Andrew C.; Smits-Seemann, Rochelle R.; Kaul, Sapna; Kirchhoff, Anne C.

In: Cancer Epidemiology, Vol. 50, 01.10.2017, p. 150-157.

Research output: Contribution to journalArticle

Ou, Judy Y. ; Spraker-Perlman, Holly ; Dietz, Andrew C. ; Smits-Seemann, Rochelle R. ; Kaul, Sapna ; Kirchhoff, Anne C. / Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients. In: Cancer Epidemiology. 2017 ; Vol. 50. pp. 150-157.
@article{637cc984ce214045812b8464052a1fd0,
title = "Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients",
abstract = "Background Survival estimates for soft tissue sarcomas (STS) and malignant bone tumors (BT) diagnosed in pediatric, adolescent, and young adult patients are not easily available. We present survival estimates based on a patient having survived a defined period of time (conditional survival). Conditional survival estimates for the short-term were calculated for patients from diagnosis to the first five years after diagnosis and for patients surviving in the long-term (up to 20 years after diagnosis). Methods We identified 703 patients who were diagnosed with a STS or BT at age ≤25 years from January 1, 1986 to December 31, 2012 at a large pediatric oncology center in Salt Lake City, Utah, United States. We obtained cancer type, age at diagnosis, primary site, and demographic data from medical records, and vital status through the National Death Index. Cancer stage was available for a subset of the cohort through the Utah Cancer Registry. Cox proportional hazards models, adjusted for age and sex, calculated survival estimates for all analyses. Results Short-term survival improves over time for both sarcomas. Short-term survival for STS from diagnosis (Year 0) did not differ by sex, but short-term survival starting from 1-year post diagnosis was significantly worse for male patients (Survival probability 1-year post-diagnosis [SP1]:77{\%} [95{\%} CI:71-83]) than female patients (SP1:86{\%} [81–92]). Survival for patients who were diagnosed at age ≤10 years (Survival probability at diagnosis [SP0]:85{\%} [79–91]) compared to diagnosis at ages 16–25 years (SP0:67{\%} [59–75]) was significantly better at all time-points from diagnosis to 5-years post-diagnosis. Survival for axial sites (SP0:69{\%} [63–75]) compared to extremities (SP0:84{\%} [79–90]) was significantly worse from diagnosis to 1-year post-diagnosis. Survival for axial BT (SP0: 64{\%} [54–74] was significantly worse than BT in the extremities (SP0:73{\%} [68–79]) from diagnosis to 3-years post diagnosis. Relapsed patients of both sarcoma types had significantly worse short-term survival than non-relapsed patients. Long-term survival for STS in this cohort is 65{\%} at diagnosis, and improves to 86{\%} 5-years post-diagnosis. BT survival improves from 51{\%} at diagnosis to 78{\%} at 5-years post-diagnosis. Conclusion Conditional survival for short- and long-term STS and BT improve as time from diagnosis increases. Short-term survival was significantly affected by patients' sex, age at diagnosis, cancer site, and relapse status.",
keywords = "Cancer, Cancer survival, Epidemiology, Pediatrics",
author = "Ou, {Judy Y.} and Holly Spraker-Perlman and Dietz, {Andrew C.} and Smits-Seemann, {Rochelle R.} and Sapna Kaul and Kirchhoff, {Anne C.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.canep.2017.08.015",
language = "English (US)",
volume = "50",
pages = "150--157",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients

AU - Ou, Judy Y.

AU - Spraker-Perlman, Holly

AU - Dietz, Andrew C.

AU - Smits-Seemann, Rochelle R.

AU - Kaul, Sapna

AU - Kirchhoff, Anne C.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background Survival estimates for soft tissue sarcomas (STS) and malignant bone tumors (BT) diagnosed in pediatric, adolescent, and young adult patients are not easily available. We present survival estimates based on a patient having survived a defined period of time (conditional survival). Conditional survival estimates for the short-term were calculated for patients from diagnosis to the first five years after diagnosis and for patients surviving in the long-term (up to 20 years after diagnosis). Methods We identified 703 patients who were diagnosed with a STS or BT at age ≤25 years from January 1, 1986 to December 31, 2012 at a large pediatric oncology center in Salt Lake City, Utah, United States. We obtained cancer type, age at diagnosis, primary site, and demographic data from medical records, and vital status through the National Death Index. Cancer stage was available for a subset of the cohort through the Utah Cancer Registry. Cox proportional hazards models, adjusted for age and sex, calculated survival estimates for all analyses. Results Short-term survival improves over time for both sarcomas. Short-term survival for STS from diagnosis (Year 0) did not differ by sex, but short-term survival starting from 1-year post diagnosis was significantly worse for male patients (Survival probability 1-year post-diagnosis [SP1]:77% [95% CI:71-83]) than female patients (SP1:86% [81–92]). Survival for patients who were diagnosed at age ≤10 years (Survival probability at diagnosis [SP0]:85% [79–91]) compared to diagnosis at ages 16–25 years (SP0:67% [59–75]) was significantly better at all time-points from diagnosis to 5-years post-diagnosis. Survival for axial sites (SP0:69% [63–75]) compared to extremities (SP0:84% [79–90]) was significantly worse from diagnosis to 1-year post-diagnosis. Survival for axial BT (SP0: 64% [54–74] was significantly worse than BT in the extremities (SP0:73% [68–79]) from diagnosis to 3-years post diagnosis. Relapsed patients of both sarcoma types had significantly worse short-term survival than non-relapsed patients. Long-term survival for STS in this cohort is 65% at diagnosis, and improves to 86% 5-years post-diagnosis. BT survival improves from 51% at diagnosis to 78% at 5-years post-diagnosis. Conclusion Conditional survival for short- and long-term STS and BT improve as time from diagnosis increases. Short-term survival was significantly affected by patients' sex, age at diagnosis, cancer site, and relapse status.

AB - Background Survival estimates for soft tissue sarcomas (STS) and malignant bone tumors (BT) diagnosed in pediatric, adolescent, and young adult patients are not easily available. We present survival estimates based on a patient having survived a defined period of time (conditional survival). Conditional survival estimates for the short-term were calculated for patients from diagnosis to the first five years after diagnosis and for patients surviving in the long-term (up to 20 years after diagnosis). Methods We identified 703 patients who were diagnosed with a STS or BT at age ≤25 years from January 1, 1986 to December 31, 2012 at a large pediatric oncology center in Salt Lake City, Utah, United States. We obtained cancer type, age at diagnosis, primary site, and demographic data from medical records, and vital status through the National Death Index. Cancer stage was available for a subset of the cohort through the Utah Cancer Registry. Cox proportional hazards models, adjusted for age and sex, calculated survival estimates for all analyses. Results Short-term survival improves over time for both sarcomas. Short-term survival for STS from diagnosis (Year 0) did not differ by sex, but short-term survival starting from 1-year post diagnosis was significantly worse for male patients (Survival probability 1-year post-diagnosis [SP1]:77% [95% CI:71-83]) than female patients (SP1:86% [81–92]). Survival for patients who were diagnosed at age ≤10 years (Survival probability at diagnosis [SP0]:85% [79–91]) compared to diagnosis at ages 16–25 years (SP0:67% [59–75]) was significantly better at all time-points from diagnosis to 5-years post-diagnosis. Survival for axial sites (SP0:69% [63–75]) compared to extremities (SP0:84% [79–90]) was significantly worse from diagnosis to 1-year post-diagnosis. Survival for axial BT (SP0: 64% [54–74] was significantly worse than BT in the extremities (SP0:73% [68–79]) from diagnosis to 3-years post diagnosis. Relapsed patients of both sarcoma types had significantly worse short-term survival than non-relapsed patients. Long-term survival for STS in this cohort is 65% at diagnosis, and improves to 86% 5-years post-diagnosis. BT survival improves from 51% at diagnosis to 78% at 5-years post-diagnosis. Conclusion Conditional survival for short- and long-term STS and BT improve as time from diagnosis increases. Short-term survival was significantly affected by patients' sex, age at diagnosis, cancer site, and relapse status.

KW - Cancer

KW - Cancer survival

KW - Epidemiology

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=85030692056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030692056&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2017.08.015

DO - 10.1016/j.canep.2017.08.015

M3 - Article

C2 - 28992567

AN - SCOPUS:85030692056

VL - 50

SP - 150

EP - 157

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

ER -